March 16, 2026 by Mohr Marketing
Safeguarding Your Firmโs Depo-Provera (MDL 3140) Inventory As the pharmaceutical liability landscape shifts toward MDL 3140 (In re: Depo-Provera Products Liability Litigation), many firms are facing a critical operational choice: build volume quickly or build volume correctly. While the potential plaintiff pool for Depo-Provera is massiveโestimated at 74 million women worldwideโthe clinical criteria required to…
Continue reading Building Your MDL 3140 Portfolio with Precision
March 15, 2026 by Mohr Marketing
Donโt settle for “intake noise.” Leverage our Compliance Shield protocol to acquire signed plaintiffs with 12+ months of usage and imaging-confirmed Intracranial Meningiomas. The Opportunity: Why Pfizer (MDL 3140) Now? Massive Solvency: Unlike other defendants, Pfizer holds immense liquidity, ensuring the “muscle” to absorb global settlements. Scientific Catalyst: A March 2024 BMJ study revealed a…
Continue reading Build a High-Value Depo-Provera Docket with Verified, Audit-Ready Retainers
March 14, 2026 by Mohr Marketing
Depo-Provera MDL Science-Back Intake: How We Filter for the “5.6x Risk” Cohort The catalyst for the Depo-Provera MDL was a bombshell study published in the British Medical Journal (BMJ) in March 2024. That study didn’t just suggest a link; it identified a specific 5.6-fold increased risk of developing meningiomas for women using the drug for…
Continue reading Depo-Provera MDL – How We Filter for the “5.6x Risk” Cohort
March 13, 2026 by Mohr Marketing
The $3B Liquidity Advantage: Why Depo-Provera is the Strategic Play for 2025-2026 As many mass torts face defendants with thinning capital, the Depo-Provera litigation stands out for its defendant solvency. Pfizer holds massive liquidity, providing the “muscle” to absorb a global settlement without the existential risks seen in other recent litigations. A Mature Docket with…
Continue reading Why Depo-Provera is the Strategic Play for 2025-2026
March 12, 2026 by Mohr Marketing
Beyond “Intake Noise”: Why Precision is the Only Way to Build a Depo-Provera Docket The pharmaceutical liability landscape has shifted with the emergence of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the numbers are massiveโan estimated 74 million users worldwideโthe legal viability of these cases hinges on a level of medical precision that…
Continue reading Why Precision is the Only Way to Build a Depo-Provera Docket
March 11, 2026 by Mohr Marketing
MDL 3140: Is Your Intake Ready for the Depo-Provera Docket? In an era where some mass tort defendants are thinly capitalized or seeking bankruptcy protection, the Depo-Provera litigation offers a rare strategic advantage: Defendant Solvency. Pfizer, the primary defendant, holds massive liquidity, giving them the “muscle” to absorb a global settlement without existential risk to…
Continue reading Defendant Solvency and the Business Case for MDL 3140
February 28, 2026 by Mohr Marketing
Mohr Marketing Deploys AI WebTrackerยฎ to Target High-Value NAION and Verified Gastroparesis Claims Amid New 2026 Medical Evidence As GLP-1 litigation enters a critical juncture, Mohr Marketing, LLC has announced the deployment of enhanced precision-targeting technologies to assist law firms in securing high-value claims. With federal case counts nearing 3,200 actions in MDL 3094 and…
Continue reading The GLP-1 Litigation Landscape has Shifted
February 24, 2026 by Mohr Marketing
Ozempic Litigation Update 2026: The Critical Shift to Objective Proof As of February 2026, the Ozempic litigation (MDL 3094 and the newly formed NAION-specific MDL 3163) has shifted from general “failure to warn” claims to a rigorous, evidence-based phase. The court now requires high-level diagnostic proof to separate drug-induced injuries from pre-existing conditions like diabetic…
Continue reading The 2026 Ozempic Litigation Pivot: From Symptoms to Scintigraphy
February 23, 2026 by Mohr Marketing
The Compliance Choice: Audit-Proof Your GLP-1 Inventory: The “Digital Birth Certificate” Solution The Ozempic (semaglutide) multidistrict litigation (MDL 3094) has entered a high-stakes phase in 2026, with a sharpened focus on medical verification and emerging evidence linking the drug to permanent injuries. Medical Evidence: NAION and Gastroparesis New clinical data is driving the current litigation…
Continue reading Compliant GLP-1 Mass Tort Case Generation: AI-Verified & Signed
February 22, 2026 by Mohr Marketing
Beyond Leads: Why “Signed Cases” are the Future of GLP-1 Mass Tort Litigation The GLP-1 litigation landscape, encompassing blockbuster drugs like Ozempic, Wegovy, and Mounjaro, is experiencing an unprecedented surge in activity. For mass tort firms, the immediate appeal of a vast claimant pool is undeniable. Yet, as the MDL progresses towards critical bellwether selections…
Continue reading GLP-1 Signed Cases: High-Quality Mass Tort Case Acquisition